109 related articles for article (PubMed ID: 7756684)
1. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Dirix L; Catimel G; Koier I; Provè A; Schrijvers D; Joossens E; De Bruijn E; Ardiet C; Evene E; Dumortier A
Anticancer Drugs; 1995 Feb; 6(1):53-63. PubMed ID: 7756684
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Dirix L; Catimel G; Verdonk R; De Bruijn E; Tranchand B; Ardiet C; Van Oosterom A
Invest New Drugs; 1995; 13(2):133-6. PubMed ID: 8617575
[TBL] [Abstract][Full Text] [Related]
3. KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study.
Schrijvers D; Catimel G; Highley M; Höppener FJ; Dirix L; De Bruijn E; Droz JP; Van Oosterom AT
Anticancer Drugs; 1999 Aug; 10(7):633-9. PubMed ID: 10507312
[TBL] [Abstract][Full Text] [Related]
4. Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
Ashizawa T; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Apr; 4(2):181-8. PubMed ID: 8490196
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
8. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Takahashi K; Yokoyama M; Takahashi H; Wakui A
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
[TBL] [Abstract][Full Text] [Related]
9. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
[TBL] [Abstract][Full Text] [Related]
10. [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
Furuse K; Yamori S; Negoro S; Fukuoka M; Takada Y; Nakai Y; Ikegami H; Fujii M; Nakajima S; Katakami N
Gan To Kagaku Ryoho; 1995 Jan; 22(1):67-76. PubMed ID: 7826080
[TBL] [Abstract][Full Text] [Related]
11. Disposition and metabolism of KW-2149, a novel anticancer agent.
Kobayashi S; Ushiki J; Takai K; Okumura S; Kono M; Kasai M; Gomi K; Morimoto M; Ueno H; Hirata T
Cancer Chemother Pharmacol; 1993; 32(2):143-50. PubMed ID: 8485809
[TBL] [Abstract][Full Text] [Related]
12. [Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group].
Niitani H; Furuse K; Fukuoka M; Hasegawa K; Taguchi T
Gan To Kagaku Ryoho; 1994 Feb; 21(2):177-87. PubMed ID: 8311488
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Nishi I; Yokoyama T; Nakao I; Harashima S; Ohashi Y; Kanko T; Saito T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
Meguro S; Nagata T; Yokoyama K; Chinen T; Yamazaki H; Kobayashi T; Isogai Y; Ogawa M
Invest New Drugs; 1984; 2(4):381-5. PubMed ID: 6511242
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
18. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer.
Furuse K; Kawahara M; Nishiwaki Y; Fukuoka M; Takada M; Miyashita M; Ohashi Y
J Clin Oncol; 1999 Oct; 17(10):3195-200. PubMed ID: 10506618
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
